Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-09-23FDA Approved: BRIMONIDINE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved Padagis Israel Pharmaceuticals Ltd's original application for Brimonidine, a generic ophthalmic solution, for lowering elevated…
-
FDA approval · 2021-09-03FDA Approved: LATANOPROST — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for latanoprost by Bausch & Lomb Incorporated to update the product labeling.
-
FDA approval · 2021-08-23FDA Approved: LATANOPROST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for LATANOPROST from Sandoz Inc., indicating an approved modification related to this generic produc…
-
FDA approval · 2021-08-18FDA Approved: BRINZOLAMIDE — Original Application (Oceanside Pharmaceuticals.)
FDA approved the original application for brinzolamide from Oceanside Pharmaceuticals, establishing a generic version of the ophthalmic drug…
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial update on efficacy and safety of bimatoprost sustained-release (SR) in open-angle glaucoma and ocular hypertension; results po…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2021-06-22FDA Approved: BRINZOLAMIDE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for brinzolamide by Sandoz Inc. to update the product labeling. The update may reflect changes to in…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial update for PHP-201 evaluating efficacy and safety in primary open angle glaucoma and ocular hypertension.
-
FDA approval · 2021-06-09FDA Approved: BETOPTIC S — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental NDA for BETOPTIC S (betaxolol hydrochloride) by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt [Phase 3]
A Phase 3 therapeutic equivalence trial comparing generic brinzolamide to Azopt in glaucoma and ocular hypertension has completed with resul…
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt [Phase 1, Phase 2]
A phase 1/2 trial comparing generic brinzolamide to Azopt for glaucoma-related indications has completed with results posted in 2021.
-
FDA approval · 2021-05-21FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application from Micro Labs Limited for generic dorzolamide hydrochloride and timolol maleate ophthalmic solutio…
-
FDA approval · 2021-05-14FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Supplemental Application (Somerset Therapeutics, LLC)
FDA approves a supplemental application for the dorzolamide hydrochloride and timolol maleate combination eye drop, a generic product used t…
-
FDA approval · 2021-05-14FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Original Application (Aurobindo Pharma Limited)
FDA approved a new generic combination eye drop of dorzolamide hydrochloride and timolol maleate for lowering intraocular pressure in open-a…
-
FDA approval · 2021-05-04FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals' original application for a generic dorzolamide hydrochloride and timolol maleate ophthalmic solution u…
-
CLINICAL_TRIALS trial_result · 2021-05-03Clinical Trial Update: A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 [Phase 2]
Phase 2 clinical trial evaluating 24-hour intraocular pressure lowering and systemic exposure of PF-04217329 in glaucoma and ocular hyperten…
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure. [Phase 2]
Phase 2 clinical trial updating safety and efficacy of PF-04217329 in patients with primary open-angle glaucoma or ocular hypertension; resu…
-
FDA approval · 2021-03-19FDA Approved: TRAVOPROST OPHTHALMIC — Original Application (Micro Labs Limited)
The FDA approved Micro Labs Limited's travoprost ophthalmic solution as an original application for reducing elevated intraocular pressure i…
-
FDA approval · 2021-03-16FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for the fixed-dose combination dorzolamide hydrochloride and timolol maleate from Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients [Phase 3]
Phase 3 trial evaluating latanoprost, timolol, and their combination for eye pressure reduction in open-angle glaucoma and ocular hypertensi…
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma [Phase 3]
A Phase 3 randomized, double-masked trial comparing evening dosing of Xalacom in glaucoma and ocular hypertension; the study is completed.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh. [Phase 4]
Phase 4 trial evaluating the intraocular pressure lowering effect of Xalacom in patients with primary open-angle glaucoma or ocular hyperten…
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension [Phase 3]
Phase 3 trial update for Xalacom and a fixed unfixed combination of latanoprost and timolol in open-angle glaucoma or ocular hypertension; t…
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A Study of Glaucoma or Ocular Hypertension in Patients Within the United States [Phase 3]
Phase 3 clinical trial update for glaucoma or ocular hypertension sponsored by Pfizer/Mylan (Viatris) has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma [Phase 3]
A Phase 3 randomized trial comparing evening dosing of Xalacom in glaucoma patients has completed, evaluating efficacy and safety in open-an…
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure [Phase 3]
Phase 3 trial investigating predictive factors for an additional 10% reduction of intra-ocular pressure in glaucoma and ocular hypertension …